Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 21065 | 374 | 32.2 | 78% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 1318 | 8021 | COMBRETASTATIN//STATHMIN//COMBRETASTATIN A 4 |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | FLAVONE ACETIC ACID | Author keyword | 61 | 86% | 8% | 31 |
| 2 | DMXAA | Author keyword | 53 | 70% | 12% | 44 |
| 3 | 5 6 DIMETHYLXANTHENONE 4 ACETIC ACID | Author keyword | 19 | 80% | 3% | 12 |
| 4 | FLAVONE 8 ACETIC ACID | Author keyword | 18 | 89% | 2% | 8 |
| 5 | AUCKLAND CANC SOC | Address | 11 | 14% | 21% | 77 |
| 6 | COLON 38 | Author keyword | 8 | 70% | 2% | 7 |
| 7 | ANTIVASCULAR | Author keyword | 8 | 39% | 4% | 15 |
| 8 | 5 6 DIMETHYLXANTHENONE 4 ACETIC ACID DMXAA | Author keyword | 6 | 100% | 1% | 4 |
| 9 | ASA404 | Author keyword | 6 | 50% | 2% | 8 |
| 10 | ANTI VASCULAR AGENT | Author keyword | 2 | 67% | 1% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | FLAVONE ACETIC ACID | 61 | 86% | 8% | 31 | Search FLAVONE+ACETIC+ACID | Search FLAVONE+ACETIC+ACID |
| 2 | DMXAA | 53 | 70% | 12% | 44 | Search DMXAA | Search DMXAA |
| 3 | 5 6 DIMETHYLXANTHENONE 4 ACETIC ACID | 19 | 80% | 3% | 12 | Search 5+6+DIMETHYLXANTHENONE+4+ACETIC+ACID | Search 5+6+DIMETHYLXANTHENONE+4+ACETIC+ACID |
| 4 | FLAVONE 8 ACETIC ACID | 18 | 89% | 2% | 8 | Search FLAVONE+8+ACETIC+ACID | Search FLAVONE+8+ACETIC+ACID |
| 5 | COLON 38 | 8 | 70% | 2% | 7 | Search COLON+38 | Search COLON+38 |
| 6 | ANTIVASCULAR | 8 | 39% | 4% | 15 | Search ANTIVASCULAR | Search ANTIVASCULAR |
| 7 | 5 6 DIMETHYLXANTHENONE 4 ACETIC ACID DMXAA | 6 | 100% | 1% | 4 | Search 5+6+DIMETHYLXANTHENONE+4+ACETIC+ACID+DMXAA | Search 5+6+DIMETHYLXANTHENONE+4+ACETIC+ACID+DMXAA |
| 8 | ASA404 | 6 | 50% | 2% | 8 | Search ASA404 | Search ASA404 |
| 9 | ANTI VASCULAR AGENT | 2 | 67% | 1% | 2 | Search ANTI+VASCULAR+AGENT | Search ANTI+VASCULAR+AGENT |
| 10 | AS1404 | 2 | 67% | 1% | 2 | Search AS1404 | Search AS1404 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | NSC 347512 | 192 | 98% | 13% | 49 |
| 2 | FLAVONE 8 ACETIC ACID | 181 | 88% | 22% | 84 |
| 3 | FLAVONE ACETIC ACID | 86 | 48% | 35% | 132 |
| 4 | XANTHENONE 4 ACETIC ACID | 73 | 96% | 6% | 23 |
| 5 | COLON 38 TUMORS | 52 | 100% | 5% | 18 |
| 6 | ANTIVASCULAR AGENT | 46 | 60% | 13% | 49 |
| 7 | 9 OXO 9H XANTHENE 4 ACETIC ACID | 26 | 100% | 3% | 11 |
| 8 | DMXAA | 22 | 66% | 6% | 21 |
| 9 | LM975 | 17 | 100% | 2% | 8 |
| 10 | MURINE RENAL CANCER | 13 | 48% | 5% | 20 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| FLAVONE ACETIC-ACID FROM LABORATORY TO CLINIC AND BACK | 1993 | 37 | 50 | 84% |
| The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer | 2008 | 19 | 25 | 76% |
| Antivascular therapy of cancer: DMXAA | 2003 | 100 | 70 | 44% |
| Immunomodulatory actions of xanthenone anticancer agents | 1997 | 21 | 56 | 86% |
| Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA) | 2011 | 2 | 45 | 80% |
| Preclinical Efficacy of Vascular Disrupting Agents in Non-Small-Cell Lung Cancer | 2011 | 6 | 64 | 56% |
| Clinical Trials of Vascular Disrupting Agents in Advanced Non-Small-Cell Lung Cancer | 2011 | 6 | 22 | 55% |
| FLAVONE 8-ACETIC ACID - OUR CURRENT UNDERSTANDING OF ITS MECHANISM OF ACTION IN SOLID TUMORS | 1989 | 27 | 12 | 100% |
| METHODOLOGICAL ASPECTS OF PHASE-I STUDIES OF NOVEL ANTICANCER AGENTS (REVIEW) | 1992 | 2 | 5 | 80% |
| Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: The experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation | 2002 | 14 | 157 | 23% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | AUCKLAND CANC SOC | 11 | 14% | 21% | 77 |
| 2 | CANC CLIN PHARMACOL GRP | 1 | 50% | 0.5% | 2 |
| 3 | ARC 1016B | 1 | 50% | 0.3% | 1 |
| 4 | AUCKLAND CANC SOC MED SCI | 1 | 50% | 0.3% | 1 |
| 5 | BALTIMORE UMB | 1 | 50% | 0.3% | 1 |
| 6 | INSERM U640CNRS UMR 8151 | 1 | 50% | 0.3% | 1 |
| 7 | INSERMCNRSUMR8151U640 | 1 | 50% | 0.3% | 1 |
| 8 | MINIST AGR PL CHEM | 1 | 50% | 0.3% | 1 |
| 9 | PULMONOL KLIN | 1 | 50% | 0.3% | 1 |
| 10 | PRECLIN IMAGING IL | 1 | 22% | 0.5% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000281790 | COMBRETASTATIN//COMBRETASTATIN A 4//COMBRETASTATINS |
| 2 | 0.0000097444 | 2 STYRYLCHROMONES//3 STYRYLCHROMONES//AMINOFLAVONE |
| 3 | 0.0000082705 | BATRACYLIN//2 LITHIOMETHYLPHENYL ISOCYANIDE//4H 3 1 BENZOXAZINES |
| 4 | 0.0000069482 | ACYL GLUCURONIDES//ACYL GLUCURONIDE//ZOMEPIRAC |
| 5 | 0.0000061494 | 1 4 ADDUCTS//BENZOFURAN 3 ONES//COPPER CATALYZED CASCADE ADDITION |
| 6 | 0.0000047890 | 2 3 4 DIARYL 5 OXO 1 2 4 TRIAZINE 6 YLIDENEACETATES//3 4 DIARYL 1 2 4 TRIAZOLO 5 CARBOXYLATES//ADEUOVIRUS |
| 7 | 0.0000047734 | IMEXON//1 4 DIHYDRO 2 3 QUINOXALINEDIONE//CYANOAZIRIDINE |
| 8 | 0.0000046137 | CARBOGEN//TUMOR HYPOXIA//TUMOR OXYGENATION |
| 9 | 0.0000045886 | PYRANES//2 APYRIMIDINE//COLOR PHOTOGRAPH |
| 10 | 0.0000045622 | THALIDOMIDE//CC 5013//CC 4047 |